01Purpose and principlesWhat the treatment does and how it fits into care.
A brain-tumour operation can serve several purposes: relieve pressure, obtain representative tissue, reduce tumour burden and improve seizure or focal symptoms. These aims may align, but not always. A deep, diffuse or eloquent lesion may be safer to biopsy than resect; a large accessible mass causing pressure may benefit from decompression; and a radiologically typical very-low-grade lesion may sometimes be monitored. The correct question is therefore not “biopsy or resection?” in isolation, but what information or benefit is needed and what neurological risk is acceptable.
Modern diagnosis combines morphology with molecular testing. Sampling error matters because heterogeneous tumours may contain higher-grade foci, and scant tissue may limit classification or predictive biomarkers. Preoperative MRI, functional mapping, intraoperative neurophysiology, image guidance and awake techniques can help maximise safe sampling or resection. NICE NG99 recommends that the surgical expertise available for suspected low-grade glioma includes awake craniotomy, functional monitoring, neurophysiology, neuroradiology and image guidance. It also explicitly recommends biopsy when surgical resection is not appropriate.
Radiotherapy deposits ionising energy in a planned target while constraining dose to normal tissue. Fractionation permits repair between treatments; stereotactic techniques deliver highly conformal treatment to selected small targets or cavities; whole-brain treatment addresses diffuse intracranial burden but carries cognitive cost. The chosen technique, dose and timing depend on histology, grade, molecular profile, residual disease, target volume, prior radiation, proximity to optic pathways or brainstem, age and expected benefit. Radiotherapy is not automatically required after every biopsy or resection.
Supportive care is concurrent, not a final fallback. NICE asks services to discuss physical, cognitive, emotional, spiritual and social needs, provide a named coordinator, offer supportive care throughout treatment and consider neurological rehabilitation assessment at diagnosis and every stage of follow-up. Patients need explanations of imaging and pathology, fertility discussion when relevant, driving advice from current rules, seizure and medicine review, and planning for work and carers. When tumour-directed treatment offers little benefit or the patient declines it, best supportive care should still be active, individualised and well coordinated.
Key points
- Biopsy establishes histological and molecular diagnosis when resection is unsafe or inappropriate; resection can add decompression and cytoreduction but must remain maximal safe, not maximal at any neurological cost.
- Treatment selection is an MDT decision integrating current WHO diagnosis, molecular markers, tumour location and extent, symptoms, performance, comorbidity, prior therapy, prognosis and informed patient priorities.
- Radiotherapy may be focal, stereotactic, fractionated or whole-brain depending on entity and target; its potential local control is balanced against acute toxicity and late cognitive, vascular, endocrine, cranial-nerve and radionecrosis risks.
- For a suspected low-grade glioma in over-16s, NICE advises considering resection within 6 months to obtain tissue and remove as much as safely possible, or biopsy when resection is not appropriate; selected typical very-low-grade lesions may be monitored.
- Supportive care begins at diagnosis and continues throughout the pathway. It includes symptom relief, seizure and steroid review, rehabilitation, cognition, communication, nutrition, psychological and social support, advance care planning and caregiver needs.
- Best supportive care is a positive treatment choice when tumour-directed therapy is unlikely to help or is declined; decisions should be revisited as function, disease and goals change.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Define whether the immediate goal is emergency decompression, diagnosis, cytoreduction, durable local control, symptom relief or information for systemic therapy. Different goals lead to different procedures.
Assess neurological baseline, cognition, performance, frailty and the lesion’s relation to language, motor, visual, brainstem and vascular structures. An anatomical possibility is not automatically a worthwhile operation.
New deficit, seizure, reduced consciousness, severe headache or vomiting after cranial surgery needs prompt examination and imaging for haemorrhage, infarction, oedema, hydrocephalus or infection.
Consider entity, target volume and number, location, prior radiation, tissue diagnosis, performance and expected survival. The least burdensome effective technique may best fit the patient’s goals.
Ask about pain, nausea, seizures, fatigue, cognition, mood, communication, swallowing, mobility, self-care, relationships, employment, finances and caregiver strain at each transition.
Provide realistic options and uncertainty in an accessible form. Cognitive or language impairment may require supported decision-making and collateral information without displacing the patient’s values.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Standard and advanced MRI reviewFirst step - Why
- Define lesion extent, eloquent relationships, target volumes and areas most likely to yield diagnostic tissue.
- Interpretation and limitations
- Enhancement and perfusion can guide sampling but do not replace pathology. Infiltrative margins extend beyond visible enhancement, and postoperative change complicates residual-tumour assessment.
- 02
Histology with integrated molecular testing - Why
- Establish current WHO entity, grade and treatment-relevant biomarkers from representative tissue.
- Interpretation and limitations
- Biopsy answers the diagnostic question only if tissue is adequate and representative. Discordant imaging, pathology and clinical behaviour warrants multidisciplinary neuropathology review or further sampling.
- 03
Functional mapping and surgical planning - Why
- Identify language, motor and other eloquent networks and plan a resection boundary that preserves meaningful function.
- Interpretation and limitations
- Functional MRI, tractography, awake testing and intraoperative mapping are selected tools, not guarantees. Negative mapping is interpreted within technique limitations and anatomical context.
- 04
Early postoperative MRI - Why
- Document extent of resection and complications at a time when imaging interpretation is most useful for MDT planning.
- Interpretation and limitations
- Residual enhancement may be tumour or early treatment change depending on sequence and timing; correlate with operative findings and later integrated pathology.
- 05
Radiotherapy planning imaging and dosimetry - Why
- Define target and organs at risk and select fractionation or stereotactic feasibility.
- Interpretation and limitations
- Plans balance tumour-control probability against normal-tissue tolerance; proximity to optic pathways or brainstem can determine technique more than a tumour label alone.
- 06
Multidomain needs assessment - Why
- Identify physical, cognitive, emotional, communication, nutritional, social and carer needs that require concurrent support.
- Interpretation and limitations
- A stable scan does not mean stable function. Reassessment at diagnosis and every follow-up stage can reveal rehabilitation or palliative needs that conventional neurological examination misses.
04Treatment approachPreparation, options, escalation and aftercare.
01Tissue and local-control pathwayNew intrinsic brain tumour in an adultFirst stepMRI shows a new intrinsic lesion and the patient is stable enough for planned specialist treatment.+
- 1Refer at radiological diagnosis to the neuro-oncology MDT, begin supportive and rehabilitation needs assessment alongside active treatment, and define the immediate goals, neurological baseline, performance, anatomy, differential and whether emergency pressure control is needed.
- 2Choose maximal safe resection when decompression, cytoreduction and adequate tissue justify the functional risk; choose biopsy when resection is unsafe or inappropriate, and reserve monitoring without tissue for carefully selected lesions with typical very-low-grade features.
- 3Obtain an integrated WHO diagnosis and treatment-relevant molecular results, verify postoperative imaging and reconsider any discordance between tissue, imaging and clinical behaviour.
- 4Select radiotherapy, systemic therapy, surveillance or combinations according to entity, grade, residual disease, function, age, prior treatment and patient preference rather than from the operation alone.
- 5Continue supportive care and rehabilitation throughout, documenting a named coordinator, results communication, toxicity monitoring and a symptom-triggered route back to the MDT.
02Supportive-care pathwayDisease-directed treatment offers limited benefitAdvanced tumour, poor performance, comorbidity or informed preference makes biopsy, resection or radiotherapy unlikely to provide proportionate benefit.+
- 1Confirm that reversible contributors and realistic disease-directed options have been considered, and explain expected benefits, burdens and uncertainty in a form the person can use.
- 2Agree active symptom priorities and offer supportive and palliative care alongside rehabilitation, psychological and social support; identify a named professional and include carers with consent.
- 3Review seizures, steroids, analgesia, nausea, mobility, swallowing, cognition, mood and practical needs, and anticipate likely deterioration and emergency preferences.
- 4Revisit decisions when function, disease or goals change; choosing best supportive care does not preclude later symptom-directed procedures when benefit becomes clear.
03Radiotherapy pathwayAdjuvant or definitive radiationDefinitiveIntegrated diagnosis and MDT review identify a potential local-control benefit from radiation.+
- 1Define target, intent, prior treatment, performance and organs at risk and explain acute and late effects relevant to the individual.
- 2Select stereotactic, focal fractionated or whole-brain technique according to entity, volume, number, location and normal-tissue constraints.
- 3Monitor neurological function, steroid need and acute toxicity during treatment and establish long-term surveillance for cognition, endocrine function, vascular effects and radionecrosis where relevant.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Dexamethasone for symptomatic tumour oedema
Dose is individualised to symptoms and source. Adult metastatic guidance considers 4–8 mg/day for mild mass-effect symptoms and higher doses such as 16 mg/day for severe symptoms, followed by the fastest clinically tolerated taper.Not routine for an asymptomatic scan. Monitor glucose, infection, psychiatric effects, sleep, proximal weakness and gastrointestinal risk; prolonged courses suppress the adrenal axis. Discuss before biopsy when primary CNS lymphoma is possible if the patient is stable.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Confirm postoperative neurological and cognitive baseline, wound status, seizure events and early imaging, and escalate any new deficit immediately.
- At every MDT transition, verify that pathology, molecular results, imaging, performance and patient goals still support the selected treatment.
- During and after radiotherapy, track neurological function, steroid need, fatigue, skin effects and nausea, then long-term cognition, endocrine, vascular and radionecrosis risks as applicable.
- NICE recommends considering neurological rehabilitation assessment at diagnosis and every stage of follow-up, not only after treatment failure.
- Use a named coordinator and symptom-triggered access route; planned surveillance never substitutes for review of new seizures, deficits, cognitive change or pressure symptoms.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Biopsy is an intervention
It can haemorrhage, seize or produce a non-diagnostic sample. Its value depends on whether representative tissue will change classification or treatment.
Resection has multiple endpoints
Extent on MRI is only one endpoint; decompression, diagnostic quality, neurological function and quality of life may matter more.
Radiation is not one treatment
Stereotactic, focal fractionated and whole-brain techniques differ in target, logistics, control and normal-tissue exposure.
Support starts early
Rehabilitation and palliative expertise can improve function and symptom control while active oncological therapy continues.
Sampling can mislead
Tumour heterogeneity means a small biopsy can under-represent grade or molecular complexity; discordance needs review rather than blind confidence.
08Common pitfallsFrequent interpretation and management errors.
- 01
Using “maximal resection” without the essential qualifier “safe” and without discussing neurological function.
- 02
Choosing biopsy because it seems minor without asking whether tissue will be adequate, representative and management-changing.
- 03
Starting radiotherapy from an imaging label when tissue or molecular diagnosis is needed and safely obtainable.
- 04
Deferring rehabilitation, communication and carer support until tumour-directed treatment finishes.
- 05
Equating best supportive care with no care rather than a coordinated, active symptom and function plan.